SEC Form 4 filed by P L Partners Capital Centerbridge
$ARA
Misc Health and Biotechnology Services
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
American Renal Associates Holdings, Inc. [ ARA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 01/25/2021 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
|||||||||||||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 01/25/2021 | J | 16,893,850 | D | (1) | 0 | I | See footnotes(2)(5) | ||
| Common Stock | 01/25/2021 | J | 523,697 | D | (1) | 0 | I | See footnotes(3)(5) | ||
| Common Stock | 01/25/2021 | J | 198,289 | D | (1) | 0 | I | See footnotes(4)(5) | ||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
| Explanation of Responses: |
| 1. The Issuer, IRC Superman Midco, LLC ("Parent") and Superman Merger Sub, Inc., a subsidiary of Parent ("Merger Sub"), are parties to that certain Agreement and Plan of Merger, dated as of October 1, 2020 (the "Merger Agreement"), pursuant to which, among other things, on January 25, 2021, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of Parent. At the effective time of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer was cancelled and converted into a right to receive $11.50 in cash. |
| 2. These shares were held by Centerbridge Capital Partners, L.P. ("Capital Partners"). |
| 3. These shares were held by Centerbridge Capital Partners Strategic, L.P. ("Capital Partners Strategic"). |
| 4. These shares were held by Centerbridge Capital Partners SBS, L.P. ("Capital Partners SBS," and, collectively with Capital Partners and Capital Partners Strategic, the "Centerbridge Funds"). |
| 5. Centerbridge Associates, L.P. is the general partner of each of Capital Partners and Capital Partners Strategic. Centerbridge Cayman GP Ltd. is the general partner of Centerbridge Associates, L.P. CCP SBS GP, LLC is the general partner of Centerbridge Partners SBS. Mark T. Gallogly retired from Centerbridge Partners, L.P. effective December 7, 2020. Jeffrey H. Aronson is the director of Centerbridge Cayman GP Ltd. and managing member of CCP SBS GP, LLC. Each of such Centerbridge entities and Mr. Aronson may be deemed to beneficially own the securities held by the Centerbridge Funds. Except for the Centerbridge Funds with respect to the securities held by such entity, each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. |
| CENTERBRIDGE CAPITAL PARTNERS, L.P. By: Centerbridge Associates, L.P., its general partner By: Centerbridge Cayman GP Ltd., its general partner By: /s/ Susanne V. Clark, Authorized Signatory | 01/27/2021 | |
| CENTERBRIDGE CAPITAL PARTNERS STRATEGIC, L.P. By: Centerbridge Associates, L.P., its general partner By: Centerbridge Cayman GP Ltd., its general partner, By: /s/Susanne V. Clark, Authorized Signatory | 01/27/2021 | |
| CENTERBRIDGE CAPITAL PARTNERS SBS, L.P. By: CCP SBS GP, LLC, its general partner, By: /s/ Susanne V. Clark, Authorized Signatory | 01/27/2021 | |
| CENTERBRIDGE ASSOCIATES, L.P. By: Centerbridge Cayman GP Ltd., its general partner By: /s/ Susanne V. Clark, Authorized Signatory | 01/27/2021 | |
| CCP SBS GP, LLC By: /s/ Susanne V. Clark, Authorized Signatory | 01/27/2021 | |
| CENTERBRIDGE CAYMAN GP LTD. By: /s/ Susanne V. Clark, Authorized Signatory | 01/27/2021 | |
| By: /s/ Jeffrey Aronson | 01/27/2021 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||